Dose escalation study of carbon ion radiotherapy for locally advanced head-and-neck cancer

Mizoe, Jun‐etsu; Tsujii, Hirohiko; Kamada, Tadashi; Matsuoka, Yosuke; Tsuji, Hiroshi; Osaka, Yasuhiro; Hasegawa, Azusa; Yamamoto, Nobuharu; Ebihara, Satoshi; Konno, Akiyoshi

doi:10.1016/j.ijrobp.2004.02.067

Cited by 179 publications

(137 citation statements)

References 20 publications

Supporting

Mentioning

124

Contrasting

Unclassified

Order By: Relevance

“…There was no discernable difference in outcomes between those treated with proton or carbon therapy although over a quarter of the patients experienced grade 3 or higher late toxicities, including three patients who developed grade 5 toxicities. Reports of small series of patients treated with carbon ions alone reveal higher control rates with lower toxicity compared with photon therapy, yet the data are still too limited draw conclusions [21]. Much like the early neutron data, particle therapy for unresectable salivary tumors may improve local control, but the benefits in overall survival have not been shown and there may be an increased risk for clinically significant toxicity, which will be better determined with longer follow-up.…”

Section: High-let Particles and Proton Therapymentioning

confidence: 99%

Outcomes after primary or adjuvant radiotherapy for salivary gland carcinoma

et al. 2016

View full text Add to dashboard Cite

Background: We report long-term outcomes of patients treated with primary radiotherapy (RT) or surgery and adjuvant RT for salivary gland malignancies. Materials and methods: From 1964 to 2012, 291 patients received primary RT (n ¼ 67) or RT combined with surgery (n ¼ 224). Results: The 5-, 10-, and 15-year local control, local-regional control, distant metastasis-free survival, cause-specific survival and overall survival rates were 82%, 77% and 73%; 77%, 72% and 67%; 74%, 70% and 70%; 70%, 59% and 54%; and 63%, 47% and 38%, respectively. Per multivariate analysis, combined surgery and RT and T stage impacted local control; overall stage and combined surgery and RT impacted local-regional control; overall stage impacted distant metastasis-free survival; and overall stage, node positivity, clinical nerve invasion, and surgery and RT impacted cause-specific and overall survival. Five percent of patients experienced grade 3 or worse toxicity. Conclusion: Combined surgery and RT improves local control, local-regional control, and cause-specific survival compared with primary RT for salivary tumors.

show abstract

Section: High-let Particles and Proton Therapymentioning

confidence: 99%

Outcomes after primary or adjuvant radiotherapy for salivary gland carcinoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…LC was also significantly improved by the application of high-precision techniques, dose-escalation and high linear energy transfer radiation [7,[33][34][35][36]. Both IMRT and FSRT provide better LC than conventional radiotherapy techniques, achieving 3-year progression-free survival (PFS) rates of 38% [37].…”

Section: Malignant Salivary Gland Tumours: Adenoid Cystic Carcinomamentioning

confidence: 99%

“…Both IMRT and FSRT provide better LC than conventional radiotherapy techniques, achieving 3-year progression-free survival (PFS) rates of 38% [37]. The highest LC rates achieved to date, at 75-100% [35,36], were achieved by neutron radiation, albeit at the cost of significant late toxicity.…”

Section: Malignant Salivary Gland Tumours: Adenoid Cystic Carcinomamentioning

confidence: 99%

Review of clinical experience with ion beam radiotherapy

Jensen

Münter²,

Debus³

2011

BJR

View full text Add to dashboard Cite

ABSTRACT. The article describes both the early development of oncology as a core discipline at the University of Heidelberg Hospital and the first steps towards ion beam treatment, from the pilot project carried out in co-operation with the Gesellschaft fü r Schwerionenforschung Darmstadt to the initial start-up of clinical service at the Heidelberg Heavy Ion Centre (HIT). We present an overview, based on data published in the literature, of the available clinical evidence relating the use of ion beam therapy to treat major indications in active particle centres. A rationale for the use of particle therapy in each of these indications is given. In view of the limited availability of data, we discuss the necessity to conduct clinical trials. We also look forward towards the next activities to be undertaken at the HIT.

show abstract

“…Çevre normal dokularda oluşturduğu hasardan dolayı fast neutron radyoterapi klinikte sınırlı bölge tümörlerinde kullanılır. [22] Fast neutron radyoterapi, hipoksik ve yavaş prolifere olan tümörlerde radyobiyolojik avantaj sağlar. Micke ve ark.nın [23] 26 nüks baş boyun kanser hastası üzerinde yaptıkları bir çalışmada hastaların ortalama sağkalım süresi 7.4 ay olarak tespit edilmiştir.…”

Section: D-fast Neutron Terapiunclassified

The final resort treatment options of recurrent head and neck cancer

Karakullukçu¹

2017

Kulak Burun Bogaz Ihtis Derg

View full text Add to dashboard Cite

ÖZBaş boyun kanserlerinde tedaviye rağmen nüks oranı %30 ila %50 arasında değişmektedir. Nüks görülen hastaların ise %50'den fazlası, kurtarma tedavisine rağmen kaybedilmektedir. Klinik uygulamada tedavi genellikle cerrahi, radyoterapi ve kemoterapiyi kapsamaktadır. Ancak nüks görülen hastalarda bu yöntemler çoğu zaman istenen sonucu verememektedir. Bu derlemede, nüks baş boyun kanserlerinin tedavisinde klinik uygulamada kullanılan yöntemler dışında kalan son yöntemler ve klinik sonuçları sunuldu.Anahtar Sözcükler: Baş boyun kanseri; nüks; tedavi. ABSTRACTDespite treatment, the recurrence rate of head and neck cancers varies between 30 and 50%. More than 50% of the patients with recurrence die, despite rescue therapy. In clinical practice, treatment usually encompasses surgery, radiotherapy, and chemotherapy. However, these methods do not often yield desirable outcomes in patients with recurrence. In this review, we present the final resort methods, except conventional methods used for the treatment of recurrent head and neck cancers in the clinical practice, and their clinical outcomes.Keywords: Head and neck cancer; recurrent; treatment.Baş boyun kanserleri tüm malignitelerin %10'unu oluşturur. Bunların %90'ını ise skuamöz hücreli karsinom oluşturur.[1] Baş boyun kanserlerinin tedavisinde cerrahi sonrası radyoterapi veya kemoradyoterapide başarısızlık oranı %30-50 arasında değişmektedir. Nüks baş ve boyun kanseri olan hastaların %50'den fazlası kurtarma tedavisine rağmen kaybedilmektedir. Cerrahi etkili bir tedavi seçeneğidir. Ancak sık-lıkla nüks tümörler, kafa tabanı, arteriyel damarlar veya çene gibi kritik yapılara infiltrasyonu nedeniyle rezektabl değildir. [2] Nüks baş boyun tümörlerinin cerrahi tedavisinde en geniş metaanaliz çalışmalarından biri olan Goodwin'in çalışmasında 32 yayın taranmış ve 1633 nüks baş boyun kanser hastası değerlen-dirilmiştir. Hastaların %99'unun daha önce radyasyon tedavisi aldığı belirtilmiştir. Bölgelerine göre beş yıllık sağkalım oranı larenks tümörün-de %47.5 (n=293), oral kavite tümöründe %43.4 (n=116), farenks tümöründe %26 (n=266) olarak bulunmuştur. Bölgelerin tümüne baktığımızda beş yıllık sağkalım oranı %39.4 (n=1080) olarak bulunmuştur.[3]

show abstract

Dose escalation study of carbon ion radiotherapy for locally advanced head-and-neck cancer

Cited by 179 publications

References 20 publications

Outcomes after primary or adjuvant radiotherapy for salivary gland carcinoma

Outcomes after primary or adjuvant radiotherapy for salivary gland carcinoma

Review of clinical experience with ion beam radiotherapy

The final resort treatment options of recurrent head and neck cancer

Contact Info

Product

Resources

About